Targeting renal cell carcinoma with a HIF-2 antagonist

Wenfang Chen, Haley Hill, Alana Christie, Min Soo Kim, Eboni Holloman, Andrea Pavia-Jimenez, Farrah Homayoun, Yuanqing Ma, Nirav Patel, Paul Yell, Guiyang Hao, Qurratulain Yousuf, Allison Joyce, Ivan Pedrosa, Heather Geiger, He Zhang, Jenny Chang, Kevin H. Gardner, Richard K. Bruick, Catherine Reeves, Tae Hyun Hwang, Kevin Courtney, Eugene Frenkel, Xiankai Sun, Naseem Zojwalla, Tai Wong, James P. Rizzi, Eli M. Wallace, John A. Josey, Yang Xie, Xian-Jin Xie, Payal Kapur, Renée M. McKay and James Brugarolas ()
Additional contact information
Wenfang Chen: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Haley Hill: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Alana Christie: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Min Soo Kim: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Eboni Holloman: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Andrea Pavia-Jimenez: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Farrah Homayoun: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Yuanqing Ma: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Nirav Patel: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Paul Yell: Parkland Health and Hospital System
Guiyang Hao: University of Texas Southwestern Medical Center
Qurratulain Yousuf: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Allison Joyce: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Ivan Pedrosa: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Heather Geiger: New York Genome Center
He Zhang: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Jenny Chang: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Kevin H. Gardner: Structural Biology Initiative, CUNY Advanced Science Research Center
Richard K. Bruick: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Catherine Reeves: New York Genome Center
Tae Hyun Hwang: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Kevin Courtney: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Eugene Frenkel: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Xiankai Sun: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Naseem Zojwalla: Peloton Therapeutics Inc.
Tai Wong: Peloton Therapeutics Inc.
James P. Rizzi: Peloton Therapeutics Inc.
Eli M. Wallace: Peloton Therapeutics Inc.
John A. Josey: Peloton Therapeutics Inc.
Yang Xie: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Xian-Jin Xie: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Payal Kapur: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
Renée M. McKay: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
James Brugarolas: Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center

Nature, 2016, vol. 539, issue 7627, 112-117

Abstract: The HIF-2 antagonist PT2399 is tested in mice bearing tumourgrafts derived from human renal cell cancers to demonstrate its efficacy, identify markers of sensitivity and characterize its effects.

Date: 2016
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/nature19796 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:539:y:2016:i:7627:d:10.1038_nature19796

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature19796

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().